Fluoxetine Carlat Reports | Carlat Publishing

Research Update

From The Carlat Hospital Psychiatry Report, Capacity Assessments

REVIEW OF: Kubiszewski P et al, JAMA Neurol 2020;e203142. Epub ahead of print. Depression after strokes is very common, affecting about 50% of stroke patients. Many such patients are treated with SSRIs, which are generally effective but potentially dangerous because they can increase the risk of bleeding due to impaired platelet aggregation. This is

Research Update

Can Antidepressants Prolong Survival in Cancer Patients?

From The Carlat Hospital Psychiatry Report, Capacity Assessments

Review Of: Shoval G et al, Depress Anxiety 2019;36(10):921–929 Many cancer patients experience depression, especially those with poor prognoses. Compared with euthymic patients, depressed cancer patients are less adherent to their cytotoxic medications, and this poor adherence can worsen their long-term survival. Yet surprisingly, some studies have

Research Update

Does Prozac Treat Repetitive and Stereotypical Behaviors in Children With Autism?

From The Carlat Child Psychiatry Report, Identity & Culture in Children and Adolescents

Review of: Reddihough DS et al, JAMA 2019;322(16):1561–1569 Restrictive, repetitive, and stereotypical behaviors in children and adolescents with autism spectrum disorder (ASD) are a common concern, and there are no FDA-approved medications for their treatment. We know that fluoxetine is effective in the treatment of obsessive-compulsive disorder i

Expert Q&A

How to Come Off a Psych Med Part 1: Antipsychotics

From The Carlat Psychiatry Report, Stopping Psych Meds Part 1

TCPR: There are a lot of books on deprescribing from the antipsychiatry movement, but your book seems to take a different approach.Dr. Gupta: The biggest difference is that the authors of this book all acknowledge that there is a place for psychotropic medications. They can be extremely beneficial for the patient in the right situation. My concern is wi

How to Select an SSRI

From The Carlat Psychiatry Report, Practical Psychotherapy

On March 14, 2012, Lexapro became the last SSRI to lose its patent, closing the book on a quarter century of science and marketing that changed and sometimes confused the way we think about antidepressants. Now that the unpublished studies have come to light and the incentives to favor one drug over another have dried up, it’s a good time to take a so

Expert Q&A

Mood and Menopause

From The Carlat Psychiatry Report, Mood and Menopause

TCPR: When does perimenopausal depression tend to start?Dr. Nonacs: It’s during the transition into menopause that women are most vulnerable to depression. And that transition can actually take quite a while, like 5–7 years. TCPR: How does it present?Dr. Nonacs: Often they’ve had a history of depression, but have done fairly well up to this point

Research Update

Optimal Antidepressant Doses in Major Depression

From The Carlat Psychiatry Report, Bipolar II

Review of: Furukawa TA et al, Lancet Psychiatry;2019;6(7):601–609 Type of study: Systematic review and meta-analysis Most antidepressants do not have a linear response curve. In other words, the benefits level off as the dose goes up. If the dose gets too high, the side effects start to outweigh those diminishing returns. What’s not clear is whe